XELJANZ XR is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Tofacitinib Citrate.
Product ID | 0069-0501_109ebd67-7ce7-4c07-9101-3afd19cefd7b |
NDC | 0069-0501 |
Product Type | Human Prescription Drug |
Proprietary Name | XELJANZ XR |
Generic Name | Tofacitinib |
Dosage Form | Tablet, Film Coated, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2016-03-07 |
Marketing Category | NDA / NDA |
Application Number | NDA208246 |
Labeler Name | Pfizer Laboratories Div Pfizer Inc |
Substance Name | TOFACITINIB CITRATE |
Active Ingredient Strength | 11 mg/1 |
Pharm Classes | Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2016-03-07 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208246 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-03-07 |
Marketing Category | NDA |
Application Number | NDA208246 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-03-07 |
Ingredient | Strength |
---|---|
TOFACITINIB CITRATE | 11 mg/1 |
SPL SET ID: | cf74ba2f-afc5-4baa-8594-979c889a5831 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
63539-501 | XELJANZ XR | XELJANZ XR |
63539-502 | XELJANZ XR | XELJANZ XR |
0069-0501 | XELJANZ | tofacitinib |
0069-0502 | XELJANZ | tofacitinib |
0069-1001 | XELJANZ | tofacitinib |
0069-1002 | XELJANZ | tofacitinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
XELJANZ 86126490 4563705 Live/Registered |
Pfizer Inc. 2013-11-22 |
XELJANZ 85678862 not registered Dead/Abandoned |
Pfizer Inc. 2012-07-17 |
XELJANZ 77688128 4099367 Live/Registered |
Pfizer Inc. 2009-03-11 |